We have located links that may give you full text access.
Safety and efficacy of inactivated COVID-19 vaccines in women vaccinated during the first trimester of pregnancy.
International Journal of Infectious Diseases : IJID 2023 March 15
OBJECTIVES: This study aimed to investigate the safety of the inactivated COVID-19 vaccines in early pregnant women in view of their adverse-effect profile and associated maternal-fetal complication, as well as to evaluate their immunogenicity.
METHODS: In this prospective observational cohort study, 232 women in their first trimester or those in the periconception period who inadvertently received two doses of inactivated COVID-19 vaccine between January 21st , 2021 and January 14th , 2022 were analyzed. Meanwhile, 735 unvaccinated early-pregnancy women were also included in the study at a case-to-control ratio of 1:3.
RESULTS: The vaccination group did not have an increased miscarriage rate compared with that of control group (P = 0.918). Furthermore, the birth defect rates in the vaccine group and control group were 0.83% and 1.0%, respectively. Vaccination did not increase the risk of small for gestational age, gestational diabetes mellitus, preterm, or hypertensive disorders of pregnancy (P>0.01). Within 12 weeks after the second dose, the inactivated vaccine effectively produced NAb against SARS-CoV-2. The NAb levels in the paired umbilical cord serum and maternal serum samples during delivery were negative in both groups. The T-cell subset remained within the normal range in both groups.
CONCLUSIONS: Therefore, our study proves that inactivated COVID-19 vaccines are safe for mothers & fetuses and effective on producing Nab against SARS-CoV-2.
METHODS: In this prospective observational cohort study, 232 women in their first trimester or those in the periconception period who inadvertently received two doses of inactivated COVID-19 vaccine between January 21st , 2021 and January 14th , 2022 were analyzed. Meanwhile, 735 unvaccinated early-pregnancy women were also included in the study at a case-to-control ratio of 1:3.
RESULTS: The vaccination group did not have an increased miscarriage rate compared with that of control group (P = 0.918). Furthermore, the birth defect rates in the vaccine group and control group were 0.83% and 1.0%, respectively. Vaccination did not increase the risk of small for gestational age, gestational diabetes mellitus, preterm, or hypertensive disorders of pregnancy (P>0.01). Within 12 weeks after the second dose, the inactivated vaccine effectively produced NAb against SARS-CoV-2. The NAb levels in the paired umbilical cord serum and maternal serum samples during delivery were negative in both groups. The T-cell subset remained within the normal range in both groups.
CONCLUSIONS: Therefore, our study proves that inactivated COVID-19 vaccines are safe for mothers & fetuses and effective on producing Nab against SARS-CoV-2.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app